Sirnaomics LtdOOTC SRNAF Stock Report

Sirnaomics Ltd. operates as a holding company. The company is headquartered in Gaithersburg, Maryland and currently employs 225 full-time employees. The company went IPO on 2021-12-30. The firm is engaged in discovering and developing drugs for indications with unmet medical needs in areas, such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics. The Company’s product pipeline has approximately 16 therapeutic candidates in the preclinical stage through Phase II clinical trials in the United States and China. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors and primary sclerosing cholangitis (PSC), and potentially lung fibrosis.